The LNP delivery system with independent intellectual property rights of CureMed has been authorized by the domestic patent.

CureMed has achieved the transfection of liver, spleen, lung, lymph node, and in vitro cells.

p Cationic lipid compounds with independent intellectual property rights, 8 cationic lipid invention patents have been applied, and 2 domestic invention patents have been authorized;

p Can achieve tissue/organ targeting;

p High transfection efficiency for a variety of cells;

p CMC process research and development completed, can achieve mass production;

p At present, 2-8 degrees stable preservation can be achieved for more than 6 months;

p Continuous R&D capability to synthesize series of compounds. At present, there are more than 2000 compounds in the library, of which more than 500 have been screened;

In order to appropriately express proteins in cells, the synthesized mRNA must be safely and efficiently delivered to the target cell cytoplasm, which is also a major challenge for mRNA drug development. An effective delivery system must have the following features:

    ①  Bind mRNA to form complexes;

    ②  Promote cellular uptake;

    ③  Protect mRNA from the erosion and degradation of intracellular and extracellular nucleases;

    ④  Release mRNA into the cytoplasm.

With the rapid development of nanotechnology, a large number of nano-drug-carrying technologies have emerged, including liposomes, nanoparticles, microemulsions, pharmacoplasts, etc. Among them, typical cationic lipids like DOTMA, DOTAP, DOPE,which are widely used in DNA, siRNA and mRNA drug delivery. In actual research and development, researchers have successfully achieved efficient mRNA delivery and protein expression.

Through hard and excellent research and development, the scientists of CureMed have established the R&D platform of compound synthesis, the library of new cationic compounds, in vivo evaluation system of LNP delivery effect and the formula optimization system, and have the ability of continuous compound synthesis and screening. At present, the RNA delivery system platform with independent intellectual property rights has been established.

Cationic lipid AX4 has the following characteristics:

    ① Suitable for both circular and linear mRNA delivery;

    ② Effective LNP has been prepared with an encapsulation rate of about 95%, and has a good effect in animal experiments.

    ③ The preparation of LNP has high repeatability, uniform particle size distribution and less than 100 nm;

    ④ At present, the test results support the storage at 4 degrees for 1 month;

    ⑤ Proprietary LNP targeted delivery system: multiple organ targeting can be achieved;

With the progress of the key technologies of mRNA, mRNA drugs may show great advantages and application prospects, and become powerful weapons to fight against diseases. In the face of the global COVID-19 epidemic and the upsurge in R&D, Krimaid actively explores the new technology of mRNA transcription biosynthesis in vitro, accelerates the R&D process of new drugs, satisfy clinical demands, benefits global patients, creates social value, and protects the healthy of people!